Aktis Oncology announced first-in-human clinical imaging and dosimetry data for AKY-2519, a targeted radiopharmaceutical for B7-H3 expressing tumors, including metastatic castration-resistant prostate cancer (mCRPC). The data showed strong tumor uptake and limited exposure to normal tissues, suggesting a favorable safety and efficacy profile compared to existing treatments. These results support ongoing Phase 1b trials in mCRPC and other solid tumors, with preliminary data expected in 2027. The findings will be presented at the 2026 ASCO Annual Meeting, highlighting AKY-2519's potential as a new therapeutic option for multiple cancer types.
Ether has surged about 11% over the past week, outperforming other major cryptocurrencies like Bitcoin, which rose 4%. This rise is driven by $96 million inflows into U.S. spot ether ETFs, mainly BlackRock’s low-fee funds, while Grayscale’s higher-fe...
Veea Inc. has announced the commercial release of VeeaONE, a full-stack AI infrastructure platform that integrates edge-to-cloud hardware and software. The platform supports VeeaWare middleware on NVIDIA Jetson and x86/Arm servers, enabling secure, l...
Virtuals Protocol has introduced customizable tokenized indexes on the Robinhood Chain, allowing users to combine multiple assets into a single token. This innovation enables users to create and manage their own asset baskets and earn fees when other...
US spot Bitcoin ETFs saw net inflows of $107.8 million on Wednesday, while Ethereum ETFs attracted $53.8 million, signaling renewed institutional interest in crypto funds. Since their launch in January 2024, Bitcoin ETFs have accumulated over $51 bil...
Kaia has signed a strategic partnership with Xilo Labs to integrate Mochi, an onchain asset management platform, into Kaia's ecosystem. This collaboration allows users to invest stablecoins into diversified portfolios backed by tokenized real-world a...
